罕见病知识库 RareSeen

进行性家族性肝内胆汁淤积症

Progressive familial intrahepatic cholestasis

定义 英文原文(暂无中文)

Progressive familial intrahepatic cholestasis (PFIC) refers to a heterogeneous group of autosomal recessive disorders of childhood that disrupt bile formation and present with cholestasis of hepatocellular origin.

别名

PFIC

基本事实

遗传方式
常染色体隐性
发病年龄
青少年期、儿童期、婴儿期、新生儿期

相关基因 7来自下位疾病

Orphanet 未在本条目上直接标注致病基因。下表由本组所属的下位疾病汇总而来,「来源条目」列给出基因实际标注在哪一个 ORPHA 条目上。

基因名称来源条目
ABCB11ATP binding cassette subfamily B member 11ORPHA:79304
ABCB4ATP binding cassette subfamily B member 4ORPHA:79305
ATP8B1ATPase phospholipid transporting 8B1ORPHA:79306
MYO5Bmyosin VBORPHA:79306
NR1H4nuclear receptor subfamily 1 group H member 4ORPHA:480476
TJP2tight junction protein 2ORPHA:480483
UTP4UTP4 small subunit processome componentORPHA:168583

临床表型 14

极常见 99–80%9

  • 凝血异常 HP:0001928
  • 胆汁淤积 HP:0001396
  • 认知功能损害 HP:0100543
  • 发育迟滞 HP:0001508
  • 肝脏肿大 HP:0002240
  • 黄疸 HP:0000952
  • 吸收不良 HP:0002024
  • 身材矮小 HP:0004322
  • 脾肿大 HP:0001744

常见 79–30%4

  • 血小板异常 HP:0001872
  • 骨成熟延迟 HP:0002750
  • 低钙血症 HP:0002901
  • 骨密度降低 HP:0004349

偶见 29–5%1

  • 肿瘤 HP:0002664

近两年的全球研究 497L2

2024/08 起在 Europe PMC 检索所得,按发表时间倒序显示最近 20 篇。标题未译成中文——自动翻译需要接入 LLM 服务,尚未引入。

  • 2026-08
    Molecular Mechanisms of Progressive Familial Intrahepatic Cholestasis
    Seminars in liver disease · DOI · Europe PMC
  • 2026-08
    Contrasting Impacts of Two ABCB11 Variants Affecting the Same Residue in Progressive Familial Intrahepatic Cholestasis Type 2
    American journal of physiology. Gastrointestinal and liver physiology · DOI · Europe PMC
  • 2026-08
    Hepatic iron accumulation is reduced in the cholestatic Mdr2-/- mouse
    Bioscience reports · DOI · Europe PMC
  • 2026-07
    From one-size-fits-all to on-demand: personalized crispr gene editing for rare genetic liver diseases
    Clinics and research in hepatology and gastroenterology · DOI · Europe PMC
  • 2026-07综述
    Parvovirus B19 infection as a trigger of acute cholestasis in heterozygous genetic BSEP deficiency: a case report and review of the literature of acute parvovirus B19-related hepatitis
    Internal and emergency medicine · DOI · Europe PMC
  • 2026-07
    Genotype-Phenotype Correlations of Monoallelic PFIC Variants in Pediatric Liver Disease: A Multicenter Retrospective Cohort Study
    American journal of medical genetics. Part A · DOI · Europe PMC
  • 2026-07
    New percentiles of gamma-glutamyl transferase serum levels in infants and the role of breastfeeding
    BMC pediatrics · DOI · Europe PMC
  • 2026-07病例报告
    Compensated Cirrhosis in a 40-Year-Old Woman With Progressive Familial Intrahepatic Cholestasis Type 3
    ACG case reports journal · DOI · Europe PMC
  • 2026-07
    Natural history and the outcome of complications of children with progressive familial intrahepatic cholestasis in a resource-limited setting: A cohort study
    Arab journal of gastroenterology : the official publication of the Pan · DOI · Europe PMC
  • 2026-07综述
    Use of genetic analysis in adult cholestatic liver disease: lessons from progressive paediatric syndromes and cohort studies
    Gut · DOI · Europe PMC
  • 2026-07
    Beyond citrulline: The diagnostic accuracy of amino acid ratios in neonatal intrahepatic cholestasis caused by citrin deficiency
    Molecular genetics and metabolism · DOI · Europe PMC
  • 2026-07系统综述综述
    Diagnostic challenges in progressive familial intrahepatic cholestasis type 3 (PFIC3) misdiagnosed as Wilson's disease: A systematic review
    Advances in clinical and experimental medicine : official organ Wrocla · DOI · Europe PMC
  • 2026-06病例报告开放获取
    Delayed Diagnosis of Low Phospholipid-Associated Cholelithiasis Syndrome, Consideration of DHCR7 Mutations
    ACG case reports journal · DOI · Europe PMC
  • 2026-06
    Rare Variants in PFIC-Related Genes Among Adults With Intrahepatic Cholestasis
    Hepatology research : the official journal of the Japan Society of Hep · DOI · Europe PMC
  • 2026-06病例报告开放获取
    Recurrent Intrahepatic Hepatolithiasis Associated With Low-Phospholipid-Associated Cholelithiasis Syndrome: An Underdiagnosed Pathology
    ACG case reports journal · DOI · Europe PMC
  • 2026-06病例报告
    Progressive Familial Intrahepatic Cholestasis Type 7 in a 4 Month Old Female, Japanese Infant: A Case Report
    Journal of paediatrics and child health · DOI · Europe PMC
  • 2026-06开放获取
    A Hematologic Masquerader: Progressive Familial Intrahepatic Cholestasis Type 3 Presenting as Anemia, Hepatosplenomegaly, and Recurrent Bleeding in a Child
    Clinical case reports · DOI · Europe PMC
  • 2026-06病例报告开放获取
    Ileal Bile Acid Transporter Inhibitors for Symptomatic Cholestasis due to Vanishing Bile Duct Syndrome in Adults
    ACG case reports journal · DOI · Europe PMC
  • 2026-06病例报告
    Resolving a Complex Neonatal Phenotype by Rapid Trio Whole-Genome Sequencing: A De Novo 11q14.3-q22.3 Deletion and a Splicing-Altering Synonymous ANK1 Variant
    Journal of clinical laboratory analysis · DOI · Europe PMC
  • 2026-06开放获取
    GGT-Normal Cholestasis in an Older Child: A Suspected Case of Benign Recurrent Intrahepatic Cholestasis From Syria
    Clinical case reports · DOI · Europe PMC

境外已获批用于本病的药物 3L2

欧盟 1 项、美国 2 项。同一药物在两地各批一次的,会分别列出。

「境外已获批」不等于「在中国能用」。中间隔着进口注册、临床急需境外新药通道、海南博鳌乐城国际医疗旅游先行区等几条路径,各有各的条件与费用。这一节能确定地告诉你的只有一件事:这个病在世界范围内已经有获得批准的药物,它叫什么名字。拿这个名字去问主治医生,是下一步最省力的做法。

药名一律保留英文原文,不作翻译——中国的药品通用名与英文名的音译经常不一致,译错会让人去找一个不存在的药。

已获孤儿药资格、尚未获批的在研药物(4 项)

孤儿药资格只是一种监管身份——它意味着监管机构认可这是罕见病用药并给予研发激励,不代表这个药已被证明有效,也不代表将来一定能上市。绝大多数最终不会成药。列在这里是为了看清有哪些方向正在被尝试。

  • Livmarli欧盟2014-01-16
    (4R,5R)-1-[[4-[[4-[3,3-dibutyl-7-(dimethylamino)-2,3,4,5- tetrahydro-4-hydroxy-1,1-dioxi…
    Treatment of progressive familial intrahepatic cholestasis
    官方记录
  • 3alpha,6beta,7beta,12alpha-tetrahydroxy-5beta-cholan-24-oic acid美国2020-10-22
    treatment of progressive familial intrahepatic cholestasis
    官方记录
  • modified human ATP binding cassette subfamily B member 11 (ABCB11) mes美国2024-07-29
    treatment of progressive familial intrahepatic cholestasis
    官方记录
  • modified human ATP binding cassette subfamily B member 4 (ABCB4) mRNA 美国2024-11-18
    treatment of progressive familial intrahepatic cholestasis
    官方记录

数据来自欧洲药品管理局(EMA)的药品与孤儿药资格公开导出表,以及美国 FDA 孤儿药资格数据库。两边口径不同:欧盟一侧取的是当前状态仍为「已授权」的药品;美国一侧记录的是「曾获批准」这一事实,FDA 的公开表不追踪药物此后是否退市(例如 Relyvrio 于 2024 年撤市,表中仍记为已获批)。请以官方记录页为准。

在中国开展的临床试验 1L2

按病名在 ClinicalTrials.gov 检索、并校验研究中心含中国大陆而来。登记状态不等于现在真的能入组——务必按 NCT 号到原站核实,并与主治医生商量。

登记为可入组 1

  • 招募中NCT07588880
    A Study of the Effectiveness, Safety and the Long-term Outcomes of Participants With Progressive Familial Intrahepatic Cholestasis (PFIC) Who Take Odevixibat (Bylvay) in China
    观察性 · 2026/04/16Ipsen
    中国研究中心 5 个:Beijing、Hunan、Nanjing、Shanghai、Xiamen

中国境外的在招试验 12L2

这些试验在中国没有研究中心,通常无法直接报名——入组一般要求在当地居住并接受随访。列在这里是因为它另有用处:看清楚全世界正在试哪些药、做到了哪一期、由谁在做。把药名和 NCT 编号记下来去问主治医生,或据此进一步查该药是否已在境外获批、是否有拓展性用药(expanded access)通道。

意大利4法国2荷兰2美国2加拿大1日本1韩国1比利时1德国1希腊1葡萄牙1西班牙1澳大利亚1

CT.gov 报告命中 12 项,此处取回并展示最近的 11 项。

  • 招募中NCT07411716
    Pediatric Evaluation and Registry for Liver Cholestasis in Canada
    观察性 · 2026/04/21Children's Hospital of Eastern Ontario
    加拿大
  • 招募中NCT06506734
    Dental Dyschromia and Quality of Life in Early Prolonged Hyperbilirubinemia
    观察性 · 2026/04/07University Hospital, Toulouse
    法国
  • 招募中NCT07293897
    A Database Study of Maralixibat (TAK-625) in Participants With Alagille Syndrome (ALGS) and Progressive Familial Intrahepatic Cholestasis (PFIC)
    观察性 · 2026/01/13Takeda
    日本
  • 招募中NCT07317193
    DEFINING THE GENETIC DRIVERS OF ADULT-ONSET CHOLESTATIC LIVER DISEASE
    不适用 · 干预性 · 2025/11/01Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
    意大利
  • 招募中NCT07185919
    A Study of the Effectiveness, Safety and the Long-term Outcomes of Participants With Progressive Familial Intrahepatic Cholestasis (PFIC) Who Take Odevixibat (Bylvay) in South Korea
    观察性 · 2025/10/30Ipsen
    韩国
  • 招募中NCT07290257
    Long-Term Low-Intervention SafEty and Clinical Outcomes Clinical Study of LivmArli® in Patients With Alagille Syndrome or Progressive Familial Intrahepatic Cholestasis in the European Union (LEAP-EU)
    IV 期 · 干预性 · 2025/09/25Mirum Pharmaceuticals, Inc.
    比利时、法国、德国、希腊、意大利、荷兰、葡萄牙、西班牙
  • 招募中NCT06777914
    Familial Intrahepatic Cholestasis-related Genes Associated with Disease Susceptibility in Hepato-biliary Cancers
    观察性 · 2024/10/22IRCCS Azienda Ospedaliero-Universitaria di Bologna
    意大利
  • 招募中NCT06781242
    Genotype-phenotype Relationship Between Cryptogenic Cholestasis and Familial Intrahepatic Cholestasis
    观察性 · 2024/01/16IRCCS Azienda Ospedaliero-Universitaria di Bologna
    意大利
  • 招募中NCT06193928
    Long-Term SafEty and Clinical Outcomes of LivmArli in Patients in the United States (LEAP-US)
    观察性 · 2023/09/21Mirum Pharmaceuticals, Inc.
    美国
  • 招募中NCT06778174
    Prospective Analysis of the Treatment of Progressive Familial Intrahepatic Cholestasis (TreatFIC)
    观察性 · 2023/02/09University Medical Center Groningen
    荷兰
  • 招募中NCT01793168
    Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
    观察性 · 2010/07Sanford Health
    澳大利亚、美国

外部标识与链接

发现这一页有错误?告诉我 · 邮件主题会自动带上本页的 ORPHA 编号

本页数据来源

  • 疾病定义、同义词、基因、表型、流行病学:Orphanet(CC BY 4.0)
  • 中文病名:Orphanet 中文包,冻结于 2020-06-01
  • 表型中文标签:HPO 简体中文翻译(CHPO 上游成果)